A key focus of our research is to be externally facing, and each collaborator will be working closely with their corresponding research pillar lead at the Antimicrobial Innovations Centre at Brunel University London.
The external partners have been carefully selected based on complementary expertise, which will allow each pillar to use both the combined expertise, as well as the collaborators’ resources to maximise research output.
The collaborators include:
- Brunel Medical School: In order to distinguish the Centre's research from other antimicrobial resistance centres, Antimicrobial Innovations Centre has partnered with the newly-founded Brunel Medical School. Our partnership will act as a bridge between active research programmes ongoing throughout the university and the clinicians that make up the medical school, bringing an increased clinical relevance and perspective to all research being undertaken by the centre members. Through offering antimicrobial research a more holistic approach, our centre can focus on delivering impactful and relevant solutions to the challenges surrounding antimicrobial resistance.
- CC Bio: A UK subsidiary of Precisio Biotix Therapeutics, CC Bio is an industry leader in precision antibacterial biological solutions, and they will be working with our first research pillar - Lab-based antimicrobial discovery and repurposing - to help with the translational development of models and lead compounds.
- Professor Richard Stabler (LSHTM): the founder and co-director of the Antimicrobial Resistance Centre at the London School of Hygiene and Translational Medicine, Professor Stabler is leading its growth into an internationally recognised hub of expertise in antimicrobial resistance.
- DeepMirror Ltd: DeepMirror will provide our researchers with access to the latest software in AI-driven drug design, through their platform for drug screening and optimisation
- Professor Shozeb Haider (School of Pharmacy, UCL): By integrating computational and experimental approaches, Professor Haider’s research has contributed to the field of structural bioinformatics, in this way elucidating the mechanisms of disease at a molecular level. Through working with Pillar 2, Professor Haider will be working with the team members to apply computational methods to develop new antimicrobial agents.
- Dr Michael Cook (School of Pharmacy, UCL): Dr Michael Cook’s team specialises in developing soft materials, such as thermo-responsive polymers, for healthcare applications; his collaboration with Pillar 3 will focus on the development of soft materials for ultrasound models using 3D printing techniques, in addition to the potential applications of these materials in various areas, including the topical/mucosal drug delivery, chemical sensing, and cell encapsulation.
- CELLINK, Ltd: CELLINK is a leading bioprinting company committed to delivering advanced products, services, and technologies crucial for understanding and mastering biology.
- Dr Laura Carter (School of Geography, University of Leeds): The University of Leeds has a well-established portfolio in antimicrobial research and hosts the CE4AMR club. Dr Laura Carter is a previous UKRI Future Leader Fellow, and her research is focused on environmental pollution and AMR. She has substantial track record in this area including Co-I on a GCRF Challenges Cluster Call on community engagement for AMR in LMICs and was a Co-I on NERCs UK-India tackling antimicrobial resistance in the environment programme.
- Antimicrobial Materials Ltd: Antimicrobial Materials Ltd is interested in developing novel solutions to prevent the persistence of multi-drug resistant pathogens in the environment, including the building and touch-contact environment; this aligns perfectly with AMIC’s goals.